CellaVision AB (STO:CEVI) presented its Q1 2025 results on April 29, showcasing strong performance across all regions despite a challenging market environment. The company’s stock has responded ...
Standardization and consistency for in-vitro diagnostics is of crucial importance, and the analysis and examination of blood samples is no exception. The Aerospray ® Hematology Pro Slide ...
CellaVision’s Q1 2026 revenue fell 14.6% year-over-year. The EMEA region saw a 32% decline due to inventory issues. The company’s EBITDA margin was 24%, impacted by lower sales. Stock price dropped 18 ...
HORIBA UK Ltd, Medical has introduced a new automated digital cell morphology solution in collaboration with CellaVision to help hematology laboratories simplify and expedite the performance of blood ...
HORIBA UK Ltd, Medical has introduced a new automated digital cell morphology solution in collaboration with CellaVision to help hematology laboratories simplify and expedite the performance of blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results